Industry news

Need trial amendments? It'll cost money and time

Brian Orelli / BioWorld

A new study in Therapeutic Innovation & Regulatory Science from the Tufts Center for the Study of Drug Development (CSDD) using data from 15 pharmaceutical companies and contract research organizations establishes price tags for the cost of implementing clinical trial amendments

Ask your doc? Consumers are so over pharma TV ads

Beth Snyder Bulik / FiercePharmaMarketing

What a difference a year has made in the life of pharma TV ads. A second annual patient view study from Treato just out found that the number of consumers who will ask their doctor about a drug after watching a TV ad dropped to just 7% this year, from 21% last year.

Game-playing patients more likely to refill meds: Study

Emily Wasserman / FiercePharma

HealthPrize Technologies has talked up gamification as a way to get patients to stick to their meds. Now, the company is trotting out new data supporting its approach. HealthPrize found that individuals participating in its digital adherence program were more likely to stick to their cholesterol-lowering meds.

An international commitment to fighting antimicrobial resistance

Victoria White / European Pharmaceutical Review

Medical professionals, businesses and government officials from around the world joined in Amsterdam on the sidelines of the ECCMID 2016 Conference, hosted by ESCMID, to declare their commitment to fight antimicrobial resistance (AMR) in a concerted effort.

What drop in VC?

Kyle Stanford / PitchBook Blog

The venture crash is coming! Alarmist headlines have recently popped up regarding the drop in venture capital suffered in 1Q. In actuality, more than $18 billion was invested during the quarter through venture deals in the U.S. alone, according to the PitchBook Platform, representing an uptick from capital invested in 4Q.

What does 'breakthrough' mean to docs and consumers? It's not the FDA definition

Beth Snyder Bulik / FiercePharmaMarketing

According to the dictionary, the word breakthrough means “a sudden, dramatic and important discovery or development.” However, what many doctors don’t know is that it doesn’t have the same meaning in the FDA drug approval process. 

IMS Institute Report Examines Medicine Use and Spending in 2015

Caroline Hroncich / BioPharm International

The IMS Institute for Healthcare Informatics released its annual Medicines Use and Spending in the U.S. report, a review of 2015 and outlook to 2020 of the medicines market. The report, officially released on April 14, 2016, analyzed medicine use in the United States, focusing specifically on spending, drivers of growth, major market segments, prescription volume, patient costs, and healthcare delivery changes.

Pharma-backed initiative delivers low-cost hep C drugs

Ben Adams / FierceBiotech

A new program run by charities and academia with the support of pharma is looking to cure 25,000 hep C patients in Africa and Southeast Asia by allowing better access to new drugs.

New imaging technique shows whether drugs work in cancer patients

Victoria White / European Pharmaceutical Review

The first cancer patient in Europe has been scanned with a revolutionary imaging technique that could enable doctors to see whether a drug is working within a day or two of starting treatment.

19 April 2016

Marinus Pharmaceuticals’ Ganaxolone IV Demonstrates Robust Efficacy in Benzodiazepine-Resistant Model of Status Epilepticus

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, presented preclinical data of ganaxolone IV, the Company’s intravenous formulation of its CNS-selective GABA_A modulator,  showing robust activity in a well-accepted and clinically translatable animal model of status epilepticus (SE). The data were presented during an oral and poster presentations at the 68^th American Academy of Neurology (AAN) Annual Meeting in Vancouver, BC, Canada, April 15-21, 2016.